Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annu... ( NEW HAVEN Conn. June 13 /- VIONPH...)

HOME >> MEDICINE >> TECHNOLOGY

Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting

Date:6/13/2008

NEW HAVEN, Conn., June 13 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that data from a previously conducted Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in elderly patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS) had been presented at the 13th Congress of the European Hematology Association (EHA) at the Bella Center in Copenhagen, Denmark. At the Congress, data were presented in a subset of 26 patients with high-risk MDS by French-American-British (FAB) Group criteria.

The median age of the patients in the subset was 71 years (range of 59-82 years). Twelve patients were diagnosed with refractory anemia with excess blasts (RAEB) and 9 patients were diagnosed with RAEB-t. Five patients were diagnosed with either chronic myelomonocytic leukemias (CMML) (3) or as unknown (2). Fifteen patients had intermediate cytogenetics and 11 had unfavorable cytogenetics. Sixteen of the patients were classified as Intermediate-2 risk by the International Prognostic Scoring System (IPSS) system (1.5-2.0), and 10 were classified as high risk (greater than or equal to 2.5).

Eight of the 26 patients had received prior treatment for their disease. Prior agents used included arsenic trioxide, thalidomide, Ara-C, imatinib mesylate, interferon, amifostine, melphalan, hydroxyurea and 5-azacitiadine.

The overall complete response rate was 38% (7 CR and 3 CRp). Three of 10 responders received prior treatment; 8 of the 10 responders received consolidation. The median (range) of overall survival for the entire patient group was 3.4 months (0.6-28.6) and the median (range) of overall survival for responders was 3.9 months (2.5-28.6).

'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
2. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
3. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
4. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
7. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
8. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
9. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
10. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois

Post Your Comments:

(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...

(Date:1/15/2014)... A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders. An emerging biologic ... according to analysts. Many of these drugs will require a ...

(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...

[0] Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users [0] Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings [0] Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach

... YORK, Feb. 17, 2011 Reportlinker.com ... report is available in its catalogue: ... 2016 - Cephalosporins, Penicillins, Macrolides and ... http://www.reportlinker.com/p0397051/Anti-Bacterials-Market-to-2016---Cephalosporins-Penicillins-Macrolides-and-Fluoroquinolones-to-Drive-the-Anti-Bacterials-Market.html ...

... Reportlinker.com announces that a new market research ... Early Stage Drug Discovery in Disease Segments ... Gene Therapies http://www.reportlinker.com/p0397053/Early-Stage-Drug-Discovery-in-Disease-Segments---Innovation-Focuses-on-Stem-Cell-Therapies-and-Gene-Therapies.html ... Segments - Innovation Focuses on Stem Cell Therapies ...

Cached Medicine Technology:Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market 2 Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market 3 Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies 2 Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies 3 Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies 4

Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies

(Date:7/9/2014)... Susan Wakulich was told she had an aneurysm, she figured ... her. , "I was devastated," said Wakulich, who is 56 ... this was a serious diagnosis. Then I met Dr. Bernard ... a less invasive procedure. It was something I didn,t even ... a multi-center U.S. clinical trial to evaluate the safety and ...

(Date:7/9/2014)... Fox Chase Cancer Center paint a relatively optimistic picture ... cancers that have spread to the chest wall or ... into the skin, regardless of size and whether they ... III and called "locally advanced" tumors, suggesting that ... with poor survival. Locally advanced breast cancers of this ...

(Date:7/9/2014)... release is available in French . ... in 14 year old teens, including brain structure and function, ... accuracy who will go on to develop binge drinking within ... conscientiousness, and other variables such as life events and a ... binge drinking. Whether or not the child had had ...

(Date:7/9/2014)... It may smell of flatulence and have a reputation for ... dosage, hydrogen sulfide is now being being found to offer ... to stroke, heart attacks and dementia. A new compound (AP39), ... the key to future therapies, by targeting delivery of very ... places inside cells. , Scientists in Exeter have already ...

(Date:7/9/2014)... with kidney and heart disease have raised concerns about ... However, in the first study to look closely at ... at the University of Pennsylvania report that older kidney ... and cardiovascular health as very healthy older people who ... ever increasing organ transplant waitlists, the authors of the ...

Breaking Medicine News(10 mins):Health News:New type of stent could help some brain aneurysm patients 2 Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2 Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3 Health News:What drives a child to abuse alcohol? 2 Health News:Rotten egg gas holds key to healthcare therapies 2 Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2

[0] New type of stent could help some brain aneurysm patients [0] Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses [0] What drives a child to abuse alcohol?[0] Rotten egg gas holds key to healthcare therapies [0] Penn study finds living kidney donation does not increase risk of death or heart disease for older

... of fruit and vegetables are less likely to develop ... with chronic obstructive pulmonary disease (COPD) are smokers or ... COPD - so there must be influences that mitigate ... ,Researchers at the University of Southampton, UK, have ...

... consume wine in moderation have healthier lifestyles overall than abstainers ... well established that moderate alcohol consumption seems to confer ... of heart disease. A new study shows that it may ... produce at least some of the beneficial effects. ...

... that doctors know the power of a common heart medication ... many patients do not take the medications. Research shows the ... the risk of early death by 20 percent. However, many ... dysfunction and, therefore, do not take the drugs. A new ...

... the most widely spread cancer all over the world. ... expected to die from breast cancer this year. Researchers ... be an important factor fueling this ever-growing epidemic.// ... 25 countries that included information on breastfeeding and childbearing ...

... A commonly used antidepressant may help women who suffer ... citalopram, marketed as Celexa, may help women who have ... from the University of Pennsylvania Medical Center in Philadelphia, ... would work. Half-cycling means the medication is started 14 ...

... According to a new research, a daily dose of a ... the "bad", or LDL, cholesterol levels in young men. Functional ... supplying essential nutrients. //There has been a trend of adding ... healthier. For example, Benecol Spread is a margarine that contains ...

Cached Medicine News:Health News: Breastfeeding may decrease Breast Cancer Risk 2

Apples keep lung disease away Drinking wine as part of a healthy living Outcome of common medications Breastfeeding may decrease Breast Cancer Risk New therapy for PMS Functional foods reduce cholesterol

... PCA Peel® formula, this peel will ... exfoliation for oilier, thicker and more ... on extremely sun damaged and thickened ... those with active/cystic acne and asphyxiated ...

It works by stimulating new growth of skin and collagen by decreasing the bond that holds dead skin cells on the surface. This allows dead cells to be removed gradually, leaving behind a layer of smo...

... LipiVage™ Fat Harvest, Wash & Transfer System ... to make fat transfer procedures simpler for ... satisfy the need for an office-based technique. ... There is no longer a need to ...

... BOTOX® Cosmetic is a simple, nonsurgical, physician-administered ... severe frown lines between the brows in ... age. It is the only treatment of ... Drug Administration (FDA). BOTOX® Cosmetic is ...

Medicine Products:

PCA Peel® with Hydroquinone & Resorcinol Exfoliating Treatment Glycolic Acid Peel LipiVage™ Fat Harvest, Wash & Transfer System BOTOX® Cosmetic Botulinum Toxin Type A